en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 266 subscribers, ranking 1 938 in the Medicine category and 5 749 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 266 subscribers.

According to the latest data from 02 July, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 111 over the last 30 days and by -32 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 29.61%. Within the first 24 hours after publication, content typically collects 10.15% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 928 views. Within the first day, a publication typically gains 1 346 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 37.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 03 July, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 266
Subscribers
-3224 hours
-1377 days
+11130 days
Posts Archive
Pharmacological Therapy ๐Ÿ”ด ู…ู…ูƒู† ู†ู†ุทูŠ miotic ู…ุซู„ ุงู„ pilocarpine ุจุงุนุชุจุงุฑ ุฑุญ ุชุณุจุจ miosis ูˆุชุณุญุจ ุงู„ู‚ุฒุญูŠุฉ ุจุนูŠุฏุง ุนู† ุงู„ุฒุงูˆูŠุฉ ๐Ÿ”ต ู…ู…ูƒู† ู†ุณุชุฎุฏู… ฮฒ blocker ุงูˆ ฮฑ2-agonist ุญุชู‰ ู†ู‚ู„ู„ ุงูุฑุงุฒ ุงู„ Aqueous Humor ๐Ÿ”ด ู…ู…ูƒู† ู†ุณุชุฎุฏู… CAi ู…ูˆุถุนูŠ ู…ุซู„ ุงู„ Dorzolamide ุงูˆ systemic ู…ุซู„ ุงู„ Acetazolamide โžค Hyperosmotic agents. :
Glycerin oral Isosorbide oral Mannitol 20% (1.5โ€“2 gm/kg infused I.V.)
ุงุญู†ู‡ ู†ุนุฑู ุชุนุฑูŠู ุงู„ุงูˆุฒู…ูˆุฒูŠุฉ ุญุฑูƒุฉ ุงู„ุณูˆุงุฆู„ ู…ู† ู…ู†ุงุทู‚ ุฐุงุช ุชุฑูƒูŠุฒ ู…ู†ุฎูุถ ุงู„ู‰ ู…ู†ุงุทู‚ ุฐุงุช ุชุฑูƒูŠุฒ ุนุงู„ูŠ ู…ู† ุฎู„ุงู„ ุบุดุงุก ู†ุตู ู†ุงูุฐ
ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ุชุนู…ู„ ุจู‡ุฐุง ุงู„ู…ุจุฏุฃุŒ ุดู„ูˆู† ุŸ ู…ู† ู†ู†ุทูŠ ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ู…ุซู„ุง Mannitol ุฑุญ ูŠูƒูˆู† ุชุฑูƒูŠุฒู‡ุง ุจุงู„ุฏู… ุนุงู„ูŠ ู‡ุฐุง ุงู„ุดูŠ ูŠุฎู„ูŠ ุงู„ุฏู… ูŠูƒูˆู† hyperosmolar ุจู…ุนู†ู‰ ุงู†ู‡ ุชุฑูƒูŠุฒ ุงู„ุฏู… ุฑุญ ูŠูƒูˆู† ุฃุนู„ู‰ ู…ู† ุชุฑูƒูŠุฒ ุงู„ุณูˆุงุฆู„ ููŠ ุงู„ุนูŠู† ูˆุชุญุฏูŠุฏุง ููŠ ุงู„ุฌุณู… ุงู„ุฒุฌุงุฌูŠ vitreous body ู‡ุฐุง ุงู„ูุฑู‚ ููŠ ุงู„ุชุฑูƒูŠุฒ ุฑุญ ูŠุณุญุจ ุงู„ุณูˆุงุฆู„ ู…ู† ู…ู†ุทู‚ุฉ ุงู„ุชุฑูƒูŠุฒ ุงู„ู‚ู„ูŠู„ (ุงู„ุนูŠู†) ุงู„ู‰ ุงู„ุงูˆุนูŠุฉ ุงู„ุฏู…ูˆูŠุฉ ู„ุชุฎููŠู ุงู„ุชุฑูƒูŠุฒ
ุฎุฑูˆุฌ ุงู„ุณูˆุงุฆู„ ู…ู† ุงู„ vitreous body ุฑุญ ูŠู‚ู„ู„ ู…ู† ุญุฌู… ุงู„ Aqueous Humor ูˆุจุงู„ุชุงู„ูŠ ูŠู†ุฎูุถ ุงู„ู€ IOP
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Treatment of primary angle-closure glaucoma PACG ุงู„ู‡ุฏู ู…ู† ุงู„ุนู„ุงุฌ: Reduce IOP quickly to preserve vision and avoid surgical pr
+1
Treatment of primary angle-closure glaucoma PACG ุงู„ู‡ุฏู ู…ู† ุงู„ุนู„ุงุฌ: Reduce IOP quickly to preserve vision and avoid surgical procedures ู†ุฎูุถ ุถุบุท ุงู„ุนูŠู† ุณุฑูŠุนุง ุญุชู‰ ู†ุญู…ูŠ ุงู„ุนุตุจ ุงู„ุจุตุฑูŠ ูˆู†ุญุงูุธ ุนู„ู‰ ุงู„ุจุตุฑ ูˆู†ุชุฌู†ุจ ุงู„ุนู…ู„ูŠุฉ ุงู„ุฌุฑุงุญูŠุฉ ุงู„ุนู„ุงุฌ ุงู„ู†ู‡ุงุฆูŠ definitive treatment ู„ู‡ุงูŠ ุงู„ุญุงู„ุฉ ู‡ูˆ ุนู…ู„ูŠุฉ ุฌุฑุงุญูŠุฉ ุงูˆ ู„ูŠุฒุฑูŠุฉ ุงุณู…ู‡ุง : Iridectomy ูŠุณูˆูˆู† ุซู‚ุจ ุตุบูŠุฑ ุฏุงุฎู„ ุงู„ู‚ุฒุญูŠุฉ ุจุญูŠุซ ูŠุณู…ุญ ุจู…ุฑูˆุฑ ุงู„ Aqueous Humor ู…ู† ุงู„ุญุฌุฑุฉ ุงู„ุฎู„ููŠุฉ ุงู„ู‰ ุงู„ุญุฌุฑุฉ ุงู„ุงู…ุงู…ูŠุฉ ู‡ุฐุง ุงู„ุงุฌุฑุงุก ูŠุณุงู‡ู… ุจูุชุญ ุงู„ุงู†ุณุฏุงุฏ ุงู„ุญุงุตู„ ููŠ ุงู„ Trabecular meshwork ู‡ุฐุง ู†ู„ุฌุฃ ุงู„ู‡ ููŠ ุญุงู„ุฉ ูุดู„ุช ูƒู„ ุงู„ุฎูŠุงุฑุงุช ุงู„ุฏูˆุงุฆูŠุฉ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุดุจุงุจ ุงู† ุดุงุก ุงู„ู„ู‡ ุชูƒูˆู†ูˆู† ุจุฎูŠุฑ ุงู‡ู„ุง ุจุงู„ุทู„ุงุจ ุงู„ู…ู†ุถู…ูŠู† ุญุฏูŠุซุง ุญูŠุงูƒู… ุงู„ู„ู‡ ูˆุงู† ุดุงุก ุงู„ู„ู‡ ุชุณุชูุงุฏูˆู† ู…ู† ุงู„ู‚ู†ุงุฉ ู‚ุฏุฑ ุงู„ุงู…ูƒุงู† ุงูƒู…ู„ ู…ูˆุถูˆุน ุงู„ glaucoma ู…ุง ุจู‚ู‰ ุดูŠ ุจูŠู‡ุง ูƒู… ู…ุนู„ูˆู…ุฉ ุจุณ

ู„ู‡ู†ุง ูƒู…ู„ู†ุง ุนู„ุงุฌุงุช POAG ุจุงุฌุฑ ุงู† ุดุงุก ุงู„ู„ู‡ ู†ุฎุชู… ุงู„ู…ูˆุถูˆุน ุจุนู„ุงุฌ ุงู„ PACG

โžค Fixed combination products 4. CAi + ฮฑ2-agonist Simbrinza Brinzolamide 1% + Brimonidine 0.2% โžค ophthalmic solution (drop) โžค
โžค Fixed combination products
4. CAi + ฮฑ2-agonist
Simbrinza Brinzolamide 1% + Brimonidine 0.2% โžค ophthalmic solution (drop) โžค one drop three times daily โžค MOA : Decreased Aqueous Humor Production and increased Uveoscleral outflow ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

โžค Fixed combination products 3. ฮฒ blocker + PG analog Xalacom Timolol 0.5% + Latanoprost 0.005% Duotrav , Travalol Timolol 0.
+5
โžค Fixed combination products
3. ฮฒ blocker + PG analog
Xalacom
Timolol 0.5% + Latanoprost 0.005%
Duotrav , Travalol
Timolol 0.5 % + Travoprost 0.004 %
Ganfort
Timolol 0.5 % + Bimatoprost 0.03%
โžค ophthalmic solution (drop) โžค one drop every night โžค MOA : Reduce Aqueous Humor production and increased Uveoscleral outflow ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

โžค Fixed combination products 2. ฮฒ blocker + ฮฑ2-agonist Combigan Timolol 0.5% + Brimonidine 0.2% โžค Ophthalmic solution (drop)
+1
โžค Fixed combination products
2. ฮฒ blocker + ฮฑ2-agonist
Combigan Timolol 0.5% + Brimonidine 0.2% โžค Ophthalmic solution (drop) โžค one drop twice daily โžค MOA : Decreased Aqueous Humor Production and increased Uveoscleral outflow ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

โžค Fixed combination products 1. CAi + ฮฒ blockers Dorzoptic plus Dorzolamide 2% : Timolol 0.5% โžค ophthalmic solution (drop) โžค
+3
โžค Fixed combination products
1. CAi + ฮฒ blockers
Dorzoptic plus Dorzolamide 2% : Timolol 0.5% โžค ophthalmic solution (drop) โžค one drop twice daily โžค MOA: Decreased Aqueous Humor Production

5. Cholinergic agents (Miotics) ุนู†ุฏ ุชู†ุดูŠุท ุงู„ู€cholinergic receptor ุงู„ู…ูˆุฌูˆุฏุฉ ููŠ ุงู„ุนูŠู† ูˆุชุญุฏูŠุฏุง M3 ุจูˆุงุณุทุฉ ุงู„ู€Ach ุฑุญ ูŠุตูŠุฑ ุงู†ู‚ุจุงุถ ุจุงู„ุนุถู„ุงุช ุงู„ู‡ุฏุจูŠุฉ
Contraction the Ciliary Muscles
ุงู†ู‚ุจุงุถ ู‡ุฐู‡ ุงู„ุนุถู„ุงุช ุฑุญ ูŠุคุฏูŠ ุงู„ู‰ ุชุถูŠูŠู‚ ุญุฏู‚ุฉ ุงู„ุนูŠู† miosis ูˆูุชุญ ุงู„ Trabecular meshwork ูˆุจุงู„ู†ุชูŠุฌุฉ ุฒูŠุงุฏุฉ ุชุตุฑูŠู ุงู„ู€aqueous humor ูˆู‡ุฐุง ุฑุญ ูŠุณุงู‡ู… ููŠ ุงู†ุฎูุงุถ ุงู„ู€IOP
โžค Pilocarpine ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ุงุฑุจุน ู…ุฑุงุช ูŠูˆู…ูŠุง โžค Carbachol ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ุซู„ุงุซ ู…ุฑุงุช ูŠูˆู…ูŠุง ุŒ ูุนุงู„ูŠุฉ ุงุทูˆู„ ู„ุงู†ู‡ ู…ู‚ุงูˆู… ู„ู„ู€AchE โžค Echothiophate ุนุจุงุฑุฉ ุนู† Irreversible AChE inhibitor ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ู…ุฑุชุงู† ููŠ ุงู„ูŠูˆู…
๏ปฟ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Acetazolamide vial iv 500mg/vial Dose : 250-500 mg by intravenous ูˆ ุญุณุจ ุงู„ุญุงู„ุฉ ุงุฐุง ูƒุงู† ุงู„ุจูŠุดู†ุช ูŠุนุงู†ูŠ ู…ู† nausea and vomiting ูˆ
Acetazolamide vial iv 500mg/vial Dose : 250-500 mg by intravenous ูˆ ุญุณุจ ุงู„ุญุงู„ุฉ ุงุฐุง ูƒุงู† ุงู„ุจูŠุดู†ุช ูŠุนุงู†ูŠ ู…ู† nausea and vomiting ูˆู…ุง ูŠูƒุฏุฑ ูŠุงุฎุฐ ุงู„ุนู„ุงุฌ by oral route ูƒุฐู„ูƒ ูู‚ุท ููŠ ุญุงู„ุงุช ุงู„ุทูˆุงุฑุฆ ุงูˆ ุงู„ุญุงู„ุงุช ุงู„ุญุงุฏุฉ ู…ู† primary angle-closure glaucoma ูˆุงู„ูŠ ู†ุญุชุงุฌ ุจูŠู‡ ุงู„ู‰ ุชู‚ู„ูŠู„ ุถุบุท ุงู„ุนูŠู† ุจุดูƒู„ ุณุฑูŠุน ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

โ Acetazolamide "diamox" โžค tablet125, 250mg โžค capsule 500mg ER โžค injection 500mg/vial ู„ุนู„ุงุฌ ุญุงู„ุฉ ุงู„ู€ POAG ูˆ ุงุฑุชูุงุน ุถุบุท ุงู„ุนูŠู†
+3
โ Acetazolamide "diamox"
โžค tablet125, 250mg โžค capsule 500mg ER โžค injection 500mg/vial
ู„ุนู„ุงุฌ ุญุงู„ุฉ ุงู„ู€ POAG ูˆ ุงุฑุชูุงุน ุถุบุท ุงู„ุนูŠู† ุงู„ู€IOP: โ— 125-250mg tablet ุญุจุงูŠุฉ ูˆุงุญุฏุฉ ู…ุฑุชูŠู† ุงู„ู‰ ุงุฑุจุน ู…ุฑุงุช ููŠ ุงู„ูŠูˆู… โ— 500mg capsule ER ู…ุฑุชูŠู† ููŠ ุงู„ูŠูˆู… ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Systemic CAi: Acetazolamide ู…ู† ู…ุง ู†ุญุตู„ ูุนุงู„ูŠุฉ ุจูˆุงุณุทุฉ ุงู„ู‚ุทุฑุงุช ู†ู„ุฌุฃ ู„ู„ุนู„ุงุฌุงุช ุงู„ุฌู‡ุงุฒูŠุฉ ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ุชู‚ู„ู„ ุงู†ุชุงุฌ ุงู„ Aqueous Humor ุจู†ุณุจุฉ 40-60% ูˆุชู‚ู„ู„ ุถุบุท ุงู„ุนูŠู† ุจู†ุณุจุฉ 25-40% ู…ุง ุงุณุชุฎุฏู…ู‡ุง ุณูˆูŠู‡ ูˆูŠ Topical CAi ู„ุงู† ู…ุงูƒูˆ ูุงุฆุฏุฉ ุงุถุงููŠุฉุŒ ูู‚ุท ุฒูŠุงุฏุฉ ุจ ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ
ุชุนุชุจุฑ ุฎุท ุนู„ุงุฌูŠ ุซุงู„ุซ third line ูˆูŠุณุชุฎุฏู… ู„ูุชุฑุฉ ู‚ุตูŠุฑุฉ
Side effects : Metabolic acidosis Nausea and vomiting, weight loss, decrease in libido Kidney stone, hyperuricemia
ุจุดูƒู„ ุนุงู… ุงู„ุงุดุฎุงุต ุงู„ูŠ ูŠุนุงู†ูˆู† ู…ู† ุญุณุงุณูŠุฉ ุงู„ุณู„ูุง ู…ู…ู†ูˆุน ู†ุณุชุฎุฏู… ุงู„ู‡ู… ู…ุฌู…ูˆุนุฉ ุงู„ Carbonic anhydrase inhibitors D-D interaction :
๐Ÿ”ด With diuretics may be cause Hypokalemia โ†“K ๐Ÿ”ด With aspirin may be increase acidosis and risk of aspirin toxicity
๐Ÿ”ต Other indications of Acetazolamide :
A. acute mountain sickness ู„ู„ูˆู‚ุงูŠุฉ ูˆู„ุนู„ุงุฌ ุฏุงุก ุงู„ู…ุฑุชูุนุงุช B. Idiopathic intracranial hypertension ู„ุนู„ุงุฌ ุงุฑุชูุงุน ุงู„ุถุบุท ุฏุงุฎู„ ุงู„ุฌู…ุฌู…ุฉ ู…ุฌู‡ูˆู„ ุงู„ุณุจุจ. ู„ุงู†ู‡ ูŠุซุจุท CA ุงู„ู…ูˆุฌูˆุฏ ููŠ ุงู„ุฏู…ุงุบ ูˆุจุงู„ุชุงู„ูŠ ูŠู‚ู„ู„ ู…ู† ุฅู†ุชุงุฌ ุงู„ุณุงุฆู„ ุงู„ุฏู…ุงุบูŠ ุงู„ู†ุฎุงุนูŠุŒ ูˆู‡ุฐุง ูŠุณุงุนุฏ ุนู„ู‰ ุชุฎููŠู ุงู„ุถุบุท ุฏุงุฎู„ ุงู„ุฌู…ุฌู…ุฉ C. Edema D. Epilepsy ูŠุณุชุฎุฏู… ุถู…ู† ุนู„ุงุฌุงุช ุงู„ุตุฑุน ุจุณุจุจ ุซุจูŠุท ุงู„ู€CA enzyme ุงู„ู…ูˆุฌูˆุฏ ููŠ ุงู„ุฌู‡ุงุฒ ุงู„ุนุตุจูŠ ูˆุจุงู„ุชุงู„ูŠ ุชุฃุซูŠุฑ ู‡ุฐุง ุงู„ุชุซุจูŠุท ุนู„ู‰ ุงู„ู…ุณุงุฑุงุช ุงู„ุนุตุจูŠุฉ
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐“„ผ๐“„น Brinzolamide "azopt" 1% โžค ophthalmic solution (drop) โžค one drop three times daily ู…ู…ูƒู† ู†ู‚ู„ู„ ุงุณุชุฎุฏุงู…ู‡ ุงู„ู‰ ู…ุฑุชูŠู† ุจุงู„ูŠูˆู… ูˆ
+2
๐“„ผ๐“„น Brinzolamide "azopt" 1% โžค ophthalmic solution (drop) โžค one drop three times daily ู…ู…ูƒู† ู†ู‚ู„ู„ ุงุณุชุฎุฏุงู…ู‡ ุงู„ู‰ ู…ุฑุชูŠู† ุจุงู„ูŠูˆู… ูˆ ุญุณุจ ุงู„ุญุงู„ุฉ โžค may be combined with other agents ูŠุณุจุจ blurred vision ุฑุคูŠุฉ ุถุจุงุจูŠุฉ ุงูƒุซุฑ ู…ู† Dorzolamide ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐“„ผ๐“„น Dorzolamide "Trusopt" 2% โžค ophthalmic solution (drop) โžค one drop three times daily ู…ู…ูƒู† ู†ู‚ู„ู„ ุงุณุชุฎุฏุงู…ู‡ ุงู„ู‰ ู…ุฑุชูŠู† ุจุงู„ูŠูˆู… ูˆ
+2
๐“„ผ๐“„น Dorzolamide "Trusopt" 2% โžค ophthalmic solution (drop) โžค one drop three times daily ู…ู…ูƒู† ู†ู‚ู„ู„ ุงุณุชุฎุฏุงู…ู‡ ุงู„ู‰ ู…ุฑุชูŠู† ุจุงู„ูŠูˆู… ูˆ ุญุณุจ ุงู„ุญุงู„ุฉ โžค may be combined with other agents ูŠุณุจุจ stinging ุญุฑู‚ุฉ ููŠ ุงู„ุนูŠู† ุงูƒุซุฑ ู…ู† Brinzolamide ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

4. Carbonic anhydrase inhibitors ู‡ุฐุง ุงู„ุงู†ุฒูŠู… Carbonic anhydrase ู…ูˆุฌูˆุฏ ููŠ ุงู„ุฌุณู… ุงู„ู‡ุฏุจูŠ ciliary body ๐Ÿ”ด ู…ุณุคูˆู„ ุนู† ุงูุฑุงุฒ ุงูŠูˆู†ุงุช ุงู„ุตูˆุฏูŠูˆู… ูˆุงู„ุจูŠูƒุงุฑุจูˆู†ุงุช ู…ู† ุงู„ุฌุณู… ุงู„ู‡ุฏุจูŠ ุงู„ู‰ ุณุงุฆู„ ุงู„ุนูŠู† ูˆุชูƒูˆูŠู† ุงู„ู€ Aqueous Humor ๐Ÿ”ต ุชุซุจูŠุท ู‡ุฐุง ุงู„ุงู†ุฒูŠู… ู…ู† ุฎู„ุงู„ ุงุฏูˆูŠุฉ Carbonic anhydrase inhibitors ุฑุญ ูŠู‚ู„ู„ ู…ู† ุงู†ุชุงุฌ ุงู„ู€ Aqueous Humor ูˆุจุงู„ุชุงู„ูŠ ุชู‚ู„ูŠู„ ุงู„ู€IOP ุงู„ุงุฏูˆูŠุฉ ู…ูˆุฌูˆุฏุฉ ุจุดูƒู„ Topical ูˆุจุดูƒู„ systemic
Topical CAi: Dorzolamide Brinzolamide
ู‡ุฐู†ูŠ ูŠุนุชุจุฑู† ูƒ second line ุงุฐุง ูุดู„ุช ุงู„ุนู„ุงุฌุงุช ุงู„ุงุณุงุณูŠุฉ ู…ู…ูƒู† ุงุณุชุฎุฏู…ู‡ู† ู„ูˆุญุฏู‡ู† ุงูˆ ูƒุนู„ุงุฌุงุช ู…ุณุงุนุฏุฉ ุชู‚ู„ู„ ุถุบุท ุงู„ุนูŠู† ุจู†ุณุจุฉ 15-26%
ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ: Transient burning and blurred vision ุญุฑู‚ุฉ ูˆุฑุคูŠุฉ ุถุจุงุจูŠุฉ ู…ุคู‚ุชุฉ Tearing, Stinging, Ocular discomfort ู†ุงุฏุฑุง ู…ู…ูƒู† ุชุณุจุจ ุงู„ุชู‡ุงุจ ู…ู„ุชุญู…ุฉ conjunctivitis ูˆุญุณุงุณูŠุฉ ุถูˆุฆูŠุฉ photophobia
๏ปฟ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐“„ผ๐“„น Apraclonidine "iopidine" 0.5% , 0.1% โžค ophthalmic solution (drop) โžค one drop before and after surgery ุงูƒุซุฑ ุดูŠ ูŠุณุชุฎุฏู… ุงุซู†
๐“„ผ๐“„น Apraclonidine "iopidine" 0.5% , 0.1%
โžค ophthalmic solution (drop)
โžค one drop before and after surgery
ุงูƒุซุฑ ุดูŠ ูŠุณุชุฎุฏู… ุงุซู†ุงุก ุงู„ุนู…ู„ูŠุงุช ุงู„ุฌุฑุงุญูŠุฉ ู‚ุจู„ ูˆุจุนุฏ ุงู„ุนู…ู„ูŠุฉ ุญุชู‰ ู†ู…ู†ุน ุงุฑุชูุงุน ุถุบุท ุงู„ุนูŠู†
โžค less lipophilicity than Brimonidine and don't cross the Blood brain barrier
ู…ุง ุนู†ุฏู‡ Selectivity ุนู„ู‰ ฮฑ2 ู…ู…ูƒู† ูŠู†ุดุท ุงู„ู€ ฮฑ1 ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุงู„ู€Brimonidine ู…ูˆุฌูˆุฏ ุจุดูƒู„ Topical gel ุฌู„ ู…ูˆุถุนูŠ ูŠุณุชุฎุฏู… ู„ุนู„ุงุฌ ุงุญู…ุฑุงุฑ ุงู„ูˆุฌู‡ ุงู„ู…ุตุงุญุจ ู„ุญุงู„ุฉ ุงู„ูˆุฑุฏูŠุฉ Rosacea ุงู„ุณุจุจ ู„ุงู†ู‡ ุงู„ู€ Brimoni
+2
ุงู„ู€Brimonidine ู…ูˆุฌูˆุฏ ุจุดูƒู„ Topical gel ุฌู„ ู…ูˆุถุนูŠ
ูŠุณุชุฎุฏู… ู„ุนู„ุงุฌ ุงุญู…ุฑุงุฑ ุงู„ูˆุฌู‡ ุงู„ู…ุตุงุญุจ ู„ุญุงู„ุฉ ุงู„ูˆุฑุฏูŠุฉ Rosacea
ุงู„ุณุจุจ ู„ุงู†ู‡ ุงู„ู€ Brimonidine ูŠุญูุฒ ุงู„ู€ฮฑ2 ูˆุจุงู„ุชุงู„ูŠ ูŠุณุจุจ ุชุถูŠูŠู‚ ููŠ ุงู„ุงูˆุนูŠุฉ ุงู„ุฏู…ูˆูŠุฉ ุจุงู„ู†ุชูŠุฌุฉ ูŠู‚ู„ ุงุญู…ุฑุงุฑ ุงู„ุฌู„ุฏ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุงูƒูˆ ุชุฑูƒูŠุจุฉ ุฎุงุตุฉ ู…ู† ุงู„ู€ Brimonidine ุงุณู…ู‡ุง alphagan P ุดู†ูˆ ูุฑู‚ู‡ุง ุนู† ุงู„ู€ alphagan ุงู„ุนุงุฏูŠุฉุŸ Alphagan P 0.1% , 0.15% ู‡ุงูŠ ุงู„ู‚ุทุฑุฉ ู…ุง
ุงูƒูˆ ุชุฑูƒูŠุจุฉ ุฎุงุตุฉ ู…ู† ุงู„ู€ Brimonidine ุงุณู…ู‡ุง alphagan P ุดู†ูˆ ูุฑู‚ู‡ุง ุนู† ุงู„ู€ alphagan ุงู„ุนุงุฏูŠุฉุŸ Alphagan P 0.1% , 0.15% ู‡ุงูŠ ุงู„ู‚ุทุฑุฉ ู…ุง ุชุญุชูˆูŠ ุนู„ู‰ Benzalkonium chloride ูƒู…ุงุฏุฉ ุญุงูุธุฉ ูˆุงู†ู…ุง ุชุญุชูˆูŠ ุนู„ู‰ purite ู‡ุฐู‡ ุงู„ู…ุงุฏุฉ ุงู‚ู„ ุชุฃุซูŠุฑุงุช ุนู„ู‰ ุงู„ุนูŠู† ูˆุงู…ุชุตุงุต ุงู„ุฏูˆุงุก ู‡ู†ุง ูŠูƒูˆู† ุงูƒุจุฑ ู†ูุณ ุงู„ุงุณุชุฎุฏุงู… ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ู…ุฑุชุงู† ุงู„ู‰ ุซู„ุงุซ ู…ุฑุงุช ุจุงู„ูŠูˆู… ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐“„ผ๐“„น Brimonidine "alphagan" 0.15% , 0.2% โžค ophthalmic solution (drop) โžค one drop bid to tid ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ู…ุฑุชุงู† ุงู„ู‰ ุซู„ุงุซ ู…ุฑุงุช ุจุง
+2
๐“„ผ๐“„น Brimonidine "alphagan" 0.15% , 0.2%
โžค ophthalmic solution (drop)
โžค one drop bid to tid
ู‚ุทุฑุฉ ูˆุงุญุฏุฉ ู…ุฑุชุงู† ุงู„ู‰ ุซู„ุงุซ ู…ุฑุงุช ุจุงู„ูŠูˆู… ูƒู„ ูกูข ุณุงุนุฉ ุงูˆ ูƒู„ ูจ ุณุงุนุงุช
โžค brimonidine have neuroprotective effect
ุชุฃุซูŠุฑ ูˆุงู‚ูŠ ู„ู„ุงุนุตุงุจ ุŒู„ุฐู„ูƒ ู…ู…ูƒู† ูŠุคุฎุฑ ุชุฏู‡ูˆุฑ ู…ุฌุงู„ ุงู„ุฑุคูŠุฉ ุงู„ู€ Brimonidine ูŠูƒูˆู† selective ุงูƒุซุฑ ุนู„ู‰ ฮฑ2 receptor ู„ุฐู„ูƒ ูŠูƒูˆู† ุงู‚ู„ ุขุซุงุฑ ุฌุงู†ุจูŠุฉ ู…ู‚ุงุฑู†ุฉ ูˆูŠ ุงู„ apraclonidine ู…ู…ูƒู† ู†ุณุชุฎุฏู…ู‡ ูƒู€ู€adjunctiveู€ู€ุนู„ุงุฌ ู…ุณุงุนุฏ ู…ุน ุงุฏูˆูŠุฉ ุฃุฎุฑู‰ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ